基于α-叠氮肉桂酸酯合成异噁唑和中氮茚衍生物的方法学分析-methodological analysis of synthesis of isoxazole and indolizine derivatives based on α - azinone cinnamate.docxVIP

目录中文摘要·····························································································1 英文摘要·····························································································2 第一章绪论························································································4 1.叠氮化合物的简介及研究进展···············································42.本章小结················································································6 参考文献····················································································7 第二章基于α-叠氮肉桂酸酯合成异噁唑衍生物的方法学研究··········9 一.引言··························································································91.异噁唑类衍生物的简介及研究进展······································9 二.α-叠氮肉桂酸酯和氯代肟的1,3-偶极环加成反应···················14 1．实验探索·············································································142.结果与讨论··········································································14 三. 实验部分················································································18 1.试剂与仪器··········································································182化合物的合成及其表征························································19 四.本章小结·················································································20 五.本章附录·················································································20 参考文献··················································································29 第二章基于α-叠氮肉桂酸酯合成中氮茚衍生物的方法学研究········31 一．引言························································································31 1.中氮茚类衍生物的简介及研究进展······································31二.α-叠氮肉桂酸酯、吡啶和α-溴代苯乙酮的多组分反应371．实验探索·············································································372.结果与讨论··········································································38 三. 实验部分·················································································45 1.试剂与仪器························································